Showing results (161-170 of 943) with videos related to
Sort By:
Pageof 95
Journal of Biomolecular Screening|March 8, 2016
Novel Biomarkers for Renal Diseases? None for the Moment (but One)Giorgio Gentile, Giuseppe RemuzziClinical Kidney Journal|March 3, 2018
Non-muscle myosins and the podocyteMarina Noris, Giuseppe RemuzziTransplantation|June 29, 2011
Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantationMonica Cortinovis, Eliana Gotti, Silvia Pradini, et al.Diabetes Care|June 23, 2010
Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trialPiero Ruggenenti, Dario Cattaneo, Stefano Rota, et al.Journal of the American Society of Nephrology : JASN|July 26, 2015
Maintenance Dialysis throughout the World in Years 1990 and 2010Bernadette Thomas, Sarah Wulf, Boris Bikbov, et al.Nephron|June 15, 2021
Long-Term Outcomes of Kidney Transplants from Older/Marginal Donors: A Cohort StudyBoris Bikbov, Piero Ruggenenti, Annalisa Perna, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 8, 2023
Effects of Octreotide-Long-Acting Release Added-on Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease: Pilot, Randomized, Placebo-Controlled, Cross-Over TrialMatias Trillini, Anna Caroli, Norberto Perico, et al.BMJ Global Health|October 27, 2017
Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countriesShuchi Anand, Yuanchao Zheng, Maria E Montez-Rath, et al.Pharmacological Research|October 22, 2011
Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo MolteniDario Cattaneo, Alexander A VinksNature Reviews. Nephrology|October 27, 2009
Transplantation: time to rethink immunosuppression by mTOR inhibitors?Marcus D Säemann, Giuseppe RemuzziPageof 95